Allergen immunotherapy (AIT) has been used to treat allergic diseases for over a hundred years. AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. A number of guidelines, consensus documents, or both are available on international area. There has been a need for a guideline abut the AIT at the national level. We aimed to overcome this need by preparing a guideline, named `Allergen Immunotherapy National Guideline 2016`. The guideline is prepared according to the evidence-based criteria and level of clinical recommendations. At the preparation period, the workgroup performed a comprehensive search of the medical literature and in addition, information from articles known to the authors was considered. At the end of the guideline, supplementary material have been added like practical aspects of schedules and dosages and samples of immunotherapy reports for Social Security Institution. Furthermore, both `Raising public awareness about allergen immunotherapy`, as a need for our patients, and strategies to increase awareness of allergen immunotherapy (AIT) among the medical community were aimed.